Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany

INTRODUCTION: While golimumab (GLM) has demonstrated efficacy in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in several randomized clinical trials with biologic-naïve patients, observational data from biologic-experienced patients are sparse. We aimed to ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Krüger, Klaus, Burmester, Gerd Rüdiger, Wassenberg, Siegfried, Thomas, Matthias H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211218/
https://www.ncbi.nlm.nih.gov/pubmed/32303994
http://dx.doi.org/10.1007/s40744-020-00204-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211218/
https://www.ncbi.nlm.nih.gov/pubmed/32303994
http://dx.doi.org/10.1007/s40744-020-00204-9

Ejemplares similares